Baloxavir marboxil

The year is drawing to the close, and biotech stocks have had a fairly good run despite the market-wide downturn in October and Novmeber. New molecular moiety (NME) approvals thus far this year totaled 52, already beating the previous year's number of 46. NMEs are active moieties that...